According to the new research report published by Precedence Research, titled “Intravenous Immunoglobulin Market (By Product: IGG, IGA, IGM, IGE, IGD; By Route of Administration: Intravenous, Subcutaneous; By Application: Hypogammaglobulinemia, Chronic Inflammatory demyelinating polyneuropathy, Immunodeficiency diseases, Myasthenia Gravis, Multifocal motor neuropathy, Idiopathic thrombocytopenic purpura, Inflammatory myopathies, Others; By End-Users; By Distribution Channel) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032 (By Product: Traditional, Advanced; By Application: Pottery, Tiles, Abrasives, Sanitary wave, Bricks & pipes, Others; By End User: Medical, Industrial, Building & Construction, Others) – Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2032”, the global intravenous immunoglobulin market size is expected to be worth around US$ 29.53 billion by 2032 and is poised to record a yearly growth rate of 7.99% from 2023 to 2032. The study investigates several elements and their consequences on the growth of the all-wheel drive market.
This report focuses on intravenous immunoglobulin market volume and value at the global level, regional level and company level. From a global perspective, this report represents the overall intravenous immunoglobulin market size by analysing historical data and future prospects. Regionally, this report focuses on several key regions: North America, Europe, the Middle East & Africa, Latin America, etc.
The research report includes specific segments by region (country), by company, by all segments. This study provides information about the growth and revenue during the historic and forecasted period of 2017 to 2032. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Download a Free Copy of Our Latest Sample Report@ https://www.precedenceresearch.com/sample/2996
The study also provides important advancements in organic and inorganic growth strategies in the worldwide intravenous immunoglobulin market. A lot of corporations are prioritizing new launches, product approvals, and other business expansion techniques. In addition, the report offers profiles of intravenous immunoglobulin market firms and market strategies. Furthermore, the research focuses on top industry participants, providing information such as company profiles, components and services offered, recent financial data, and key developments.
Intravenous Immunoglobulin Market Report Scope
| Report Coverage | Details |
| Market Size in 2023 | USD 14.78 Billion |
| Market Size by 2032 | USD 29.53 Billion |
| Growth Rate from 2023 to 2032 | CAGR of 7.99% |
| Largest Market | North America |
| Base Year | 2022 |
| Forecast Period | 2023 to 2032 |
| Segments Covered | By Product, By Route of Administration, By Application, By End-Users, and By Distribution Channel |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Also read: High Barrier Packaging Films Market Size US$ 27.11 Billion by 2032
Market Key Players
Company profiles have been included in the report, which include essentials such as product portfolio, key strategies, along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through a matrix for all the prominent players, thus providing readers with actionable insights, which helps in thoughtfully presenting market status and predicting the competition level in the intravenous immunoglobulin market.
Some of the prominent players in the intravenous immunoglobulin market include
- Biotest AG
- Octapharma AG
- LFB Biotechnologies
- Grifols SA
- CSL Behring
- China Biologics Products Inc.
- Kedrion Biopharma
- BDI Pharma Inc.
Intravenous Immunoglobulin Market Segmentations
By Product
- IGG
- IGA
- IGM
- IGE
- IGD
By Route of Administration
- Intravenous
- Subcutaneous
By Application
- Hypogammaglobulinemia
- Chronic Inflammatory demyelinating polyneuropathy (CIDP)
- Immunodeficiency diseases
- Myasthenia Gravis
- Multifocal motor neuropathy
- Idiopathic thrombocytopenic purpura (ITP)
- Inflammatory myopathies
- Specific antibody deficiency
- Guillain-Barre syndrome
By End-Users
- Hospitals
- Homecare
- Specialty Clinics
By Distribution Channel
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacies
By Geography
- North America
- Europe
- Asia-Pacific
- Latin America
- Middle East and Africa
Report Objectives
- To define, segment, and project the global market size for intravenous immunoglobulin market
- To understand the structure of the market by identifying its various sub-segments
- To provide detailed information about the key factors influencing the growth of the market (drivers, restraints, opportunities, and industry-specific challenges)
- To analyse the micro-markets, with respect to individual growth trends, future prospects, and their contributions to the total market
- To project the size of the market and its submarkets, in terms of value, with respect to global. (along with their respective key countries)
- To profile key players and comprehensively analyse their core competencies
- To understand the competitive landscape and identify major growth strategies adopted by players across the globe.
- To analyse the competitive developments such as expansions & investments, new product launches, mergers & acquisitions, joint ventures, and agreements
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Intravenous Immunoglobulin Market
5.1. COVID-19 Landscape: Intravenous Immunoglobulin Industry Impact
5.2. COVID 19 – Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Intravenous Immunoglobulin Market, By Product
8.1. Intravenous Immunoglobulin Market Revenue and Volume, by Product, 2023-2032
8.1.1. IGG
8.1.1.1. Market Revenue and Volume Forecast (2020-2032)
8.1.2. IGA
8.1.2.1. Market Revenue and Volume Forecast (2020-2032)
8.1.3. IGM
8.1.3.1. Market Revenue and Volume Forecast (2020-2032)
8.1.4. IGE
8.1.4.1. Market Revenue and Volume Forecast (2020-2032)
8.1.5. IGD
8.1.5.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 9. Global Intravenous Immunoglobulin Market, By Route of Administration
9.1. Intravenous Immunoglobulin Market Revenue and Volume, by Route of Administration, 2023-2032
9.1.1. Intravenous
9.1.1.1. Market Revenue and Volume Forecast (2020-2032)
9.1.2. Subcutaneous
9.1.2.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 10. Global Intravenous Immunoglobulin Market, By Application
10.1. Intravenous Immunoglobulin Market Revenue and Volume, by Application, 2023-2032
10.1.1. Hypogammaglobulinemia
10.1.1.1. Market Revenue and Volume Forecast (2020-2032)
10.1.2. Chronic Inflammatory demyelinating polyneuropathy (CIDP)
10.1.2.1. Market Revenue and Volume Forecast (2020-2032)
10.1.3. Immunodeficiency diseases
10.1.3.1. Market Revenue and Volume Forecast (2020-2032)
10.1.4. Myasthenia Gravis
10.1.4.1. Market Revenue and Volume Forecast (2020-2032)
10.1.5. Multifocal motor neuropathy
10.1.5.1. Market Revenue and Volume Forecast (2020-2032)
10.1.6. Idiopathic thrombocytopenic purpura (ITP)
10.1.6.1. Market Revenue and Volume Forecast (2020-2032)
10.1.7. Inflammatory myopathies
10.1.7.1. Market Revenue and Volume Forecast (2020-2032)
10.1.8. Specific antibody deficiency
10.1.8.1. Market Revenue and Volume Forecast (2020-2032)
10.1.9. Guillain-Barre syndrome
10.1.9.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 11. Global Intravenous Immunoglobulin Market, By End-Users
11.1. Intravenous Immunoglobulin Market Revenue and Volume, by End-Users, 2023-2032
11.1.1. Hospitals
11.1.1.1. Market Revenue and Volume Forecast (2020-2032)
11.1.2. Homecare
11.1.2.1. Market Revenue and Volume Forecast (2020-2032)
11.1.3. Specialty Clinics
11.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 12. Global Intravenous Immunoglobulin Market, By Distribution Channel
12.1. Intravenous Immunoglobulin Market Revenue and Volume, by Distribution Channel, 2023-2032
12.1.1. Hospital Pharmacy
12.1.1.1. Market Revenue and Volume Forecast (2020-2032)
12.1.2. Retail Pharmacy
12.1.2.1. Market Revenue and Volume Forecast (2020-2032)
12.1.3. Online Pharmacies
12.1.3.1. Market Revenue and Volume Forecast (2020-2032)
Chapter 13. Global Intravenous Immunoglobulin Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.1.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.1.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.1.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.1.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.1.6. U.S.
13.1.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.1.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.1.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.1.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.1.6.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.1.7.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.1.7.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.1.7.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.1.7.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2. Europe
13.2.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.6. UK
13.2.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.7. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.8. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.9. Germany
13.2.9.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.9.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.9.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.10. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.11. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.12. France
13.2.12.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.12.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.12.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.12.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.13. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.2.14. Rest of Europe
13.2.14.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.2.14.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.2.14.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.2.14.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.2.15. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3. APAC
13.3.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.6. India
13.3.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.8. China
13.3.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.8.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.8.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.10. Japan
13.3.10.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.10.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.10.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.10.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.3.11. Rest of APAC
13.3.11.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.3.11.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.3.11.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.3.11.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.3.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4. MEA
13.4.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.6. GCC
13.4.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.8. North Africa
13.4.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.8.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.8.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.9. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.10. South Africa
13.4.10.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.10.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.10.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.10.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.10.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.4.11. Rest of MEA
13.4.11.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.4.11.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.4.11.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.4.11.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.4.11.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5. Latin America
13.5.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.5.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.5.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.5.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.5.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5.6. Brazil
13.5.6.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.5.6.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.5.6.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.5.6.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.5.7. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
13.5.8. Rest of LATAM
13.5.8.1. Market Revenue and Volume Forecast, by Product (2020-2032)
13.5.8.2. Market Revenue and Volume Forecast, by Route of Administration (2020-2032)
13.5.8.3. Market Revenue and Volume Forecast, by Application (2020-2032)
13.5.8.4. Market Revenue and Volume Forecast, by End-Users (2020-2032)
13.5.8.5. Market Revenue and Volume Forecast, by Distribution Channel (2020-2032)
Chapter 14. Company Profiles
14.1. Biotest AG
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. Octapharma AG
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. LFB Biotechnologies
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Grifols SA
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. CSL Behring
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. China Biologics Products Inc.
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. Kedrion Biopharma
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. BDI Pharma Inc.
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms
Why should you invest in this report?
If you are aiming to enter the global intravenous immunoglobulin market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for intravenous immunoglobulin are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2023-2030 so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.pharma-geek.com
